Please assess the completion status of the following clinical trial:

Trial Title: VAXCHORA Pediatric Study to Assess Safety and Immunogenicity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Male or Female~* Between 2 and \<18 years of age on Day 1~* In general good health~* Able and willing to provide informed assent for study participation~* Primary caregiver is able and willing to provide informed consent for study participation~* (for females of childbearing potential) Using an acceptable method of contraception through Day 29~Exclusion Criteria:~* Current acute gastrointestinal illness or loose stools within 3 days of Day 1 visit~* Current acute febrile illness~* History of cholera infection~* History of cholera vaccination~* History of severe allergic reaction (e.g. anaphylaxis) to any ingredient of VAXCHORA~* Congenital or acquired immunodeficiency~* Pregnancy (for females of childbearing potential)~* Any other condition that, in the opinion of the Investigator, creates an unacceptable risk to the subject~* Any other condition that, in the opinion of the Investigator, will interfere with the conduct of the study or the validity of the data~* Duration of \>2 weeks of abnormal stool pattern, defined as \<3 stools per week or \>2 stools per day in the past 6 months~* Regular use of laxatives in the past 6 months~* History of enterotoxigenic E. coli infection~* Travel to cholera-endemic area in the previous 5 years~* Nursing/Breastfeeding~* Received or plans to receive the following from 14 days prior to the study vaccination through 11 days after vaccination: Any other licensed vaccines, antibiotics, or chloroquine~* Received or plans to receive any other investigational agent throughout the main study (Day 181)

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1 (active, 12-17 yrs) (Type: EXPERIMENTAL): Subjects aged 12 - 17 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181. Cohort 1 subjects that continued in the long-term follow-up sub-study had visits on days 365, 547 and 730.
- Cohort 1 (placebo, 12 - 17 yrs) (Type: PLACEBO_COMPARATOR): Subjects aged 12 - 17 were administered a 100 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.
- Cohort 2 (active, 6 - 11 yrs) (Type: EXPERIMENTAL): Subjects aged 6 - 11 were administered a 100 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181.
- Cohort 2 (placebo, 6 - 11 yrs) (Type: PLACEBO_COMPARATOR): Subjects aged 6 - 11 were administered a 100 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.
- Cohort 3 (active, 2 - 5 yrs) (Type: EXPERIMENTAL): Subjects aged 2 - 5 were administered a 50 mL oral dose of Vaxchora vaccine on Day 1, and had study visits on Day 11, 29, 91 and 181.
- Cohort 3 (placebo, 2 - 5 yrs) (Type: PLACEBO_COMPARATOR): Subjects aged 2-5 were administered a 50 mL oral dose of 0.9% saline on Day 1, and had study visits on Day 11, 29, 91 and 181.
- Historical Control: Adult Bridging Population (Type: OTHER): This arm consists of historical data from Vaxchora vaccine subjects from study PXVX-VC-200-004. The data was included in study PXVX-VC-200-006 as a comparator bridging population for the Day 11 seroconversion. NCT02094586 PubMed ID:29317118

Based on this trial design, predict the completion outcome and termination type (if applicable).